Dark Stars in Inflammation: Astrocytes in the Neurodegenerating Brain
Posted on: 10 June 2015
Researchers from Trinity College Dublin have discovered that specialised ‘astrocytes’ abandon their posts as protectors and repairers of the brain when primed by the neurodegeneration of cells around them.
Astrocytes, named as a result of their star-shaped appearance, function in healthy brains to assist with normal brain function and metabolism.
However, the researchers from Trinity’s School of Biochemistry and Immunology have now demonstrated that these cells play a major role in the inflammatory hypersensitivity of the degenerating brain, by responding in an inappropriate and exaggerated fashion when stimulated by inflammation around them.
This discovery has important implications for the management of neurodegenerative conditions such as stroke and Parkinson’s and Alzheimer’s diseases.
In findings just published in the Journal of Neuroscience, the research group of Wellcome Trust Research Professor, Colm Cunningham, showed that stimulated astrocytes produce exaggerated amounts of molecules known as chemokines, which mobilise and recruit large numbers of inflammatory cells from the periphery to the brain. Normally, this process is tightly regulated in the young, healthy brain.
The chemokines CCL2 and CXCL1 are synthesised when the brain is exposed to acute pro-inflammatory cytokines, such as those produced during acute injury to the brain or during neurodegeneration.
These same chemokines were produced at much greater levels, however, when astrocytes of the neurodegenerating brain were similarly challenged. This in turn led to a large infiltration of neutrophils and monocytes, which act as key parts of the immune system, but which can contribute to negative brain outcomes when infiltration is uncontrolled and inflammation is excessive.
Crucially, this discovery expands our knowledge of the inflammatory vulnerability of the aging and degenerating brain and hints at strategies that could lessen this susceptibility.
Professor Cunningham said: “If one recognises the mechanisms by which the brain becomes susceptible to the effects of co-morbidities and environmental insults, one can then lessen their effects, irrespective of whether these strategies target the primary pathology. It is possible that targeting chemokines, or the inflammatory cells that produce them, may have protective effects in vulnerable patients.”
Professor Cunningham is funded by a Wellcome Trust Senior Research Fellowship, while Edel Hennessy, a PhD student who performed much of the research, was supported by a Trinity Foundation College Award.
Medical Xpress, June 10th
Health Canal, June 10th
Thomas Deane, Media Relations Officer | firstname.lastname@example.org | +353 1 896 4685